A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

Neoplasms, Hematologic Clinical Trial

Official title: A Phase 2 Study of LY2784544 in Patients With Myeloproliferative Neoplasms

Status Active, not recruiting

Clinical Trial Summary

The primary purpose of this study is to measure the response rate in participants with the myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) when treated with LY2784544, including those who have demonstrated an intolerance to, failure of primary response to, or have demonstrated disease progression while on ruxolitinib.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Hematologic Neoplasms
• Myeloproliferative Disorders
• Neoplasms
• Neoplasms, Hematologic

• NCT number: NCT01594723
• Study type: Interventional
• Source: Eli Lilly and Company
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: May 22, 2012
• Completion date: December 2024